A Randomized, Placebo-Controlled, Phase 1 Study Designed to Assess the Safety, Tolerability, Pharmacokinetics, and Food Effect of PTI-808 in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 18 Aug 2017
At a glance
- Drugs PTI 808 (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Proteostasis Therapeutics
- 31 Jul 2017 Status changed from planning to recruiting, according to a Proteostasis Therapeutics media release.
- 04 Jul 2017 New trial record
- 23 Jun 2017 According to a Proteostasis Therapeutics media release, the company has filed an Investigational New Drug application with the U.S. FDA. to initiate this trial in July 2017.